A new study has found a significant association between the use of GLP-1s such as Ozempic and Wegovy with a higher risk of developing a serious eye condition in patients with diabetes. Here are four t ...

Researchers also evaluated participants for weight changes, pain, adverse events, and labs. Semaglutide appeared to benefit participants more than the placebo. Almost 63% of participants who ...

Findings showed a 13.6% reduction in body weight in the semaglutide 25 mg group compared with a 2.2% reduction in the placebo group. The Food and Drug Administration (FDA) has accepted for review ...

Using semaglutide injections, scientists were able to reverse life-threatening cases of liver disease in a new clinical trial published in The New England Journal of Medicine. Semaglutide ...

“The results from this landmark study across 37 countries provide strong evidence that semaglutide can help patients with MASH by not only improving liver health, but also addressing the ...

More than half of adults with MASH receiving semaglutide had resolution of steatohepatitis at 72 weeks. A reduction in liver fibrosis stage was observed among 36.8% of the semaglutide group.

Results from the ESSENCE Phase III clinical trial published in the New England Journal of Medicine show treating patients with semaglutide can halt and even reverse liver disease. The placebo ...

Semaglutide is the active ingredient in certain brand-name medications prescribed for obesity, type 2 diabetes, and more. Semaglutide belongs to the glucagon-like peptide-1 (GLP-1) receptor ...

Semaglutide supports weight loss in MASLD/MASH for all diabetes groups The medication shows consistent effectiveness across groups, with no major differences in weight loss By reducing weight and ...